Amarin Corp Plc (AMRN)

[Dancing in the dark]

"Unnecessary. The existence of direct infringement is not a question. But it is not enough, specific action should be proved also. "

So manufacturing of generic icosapent ethyl is not "specific action" but encapsulation, packaging and importation then ultimately consumption by patients with the reduce-it indication, is? Or is not?

I keep going back to production limits. If jointly the generic icosapent ethyl manufacturers produce more generic icosapent ethyl than is required to treat patients with triglycerides >500, the excess production is intended for sale to patients with the reduce-it indication.